Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Foot and mouth disease virus vaccine composition

A technology of foot-and-mouth disease virus and vaccine composition, which is applied in the direction of vaccines, viruses, and viral peptides, can solve the problems that immunity can only be maintained for a few months, and it is difficult to develop a vaccine, so as to achieve a good effect of preventing FMD

Pending Publication Date: 2022-04-29
株式会社准绳生命科学
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Furthermore, due to the many mutations of one serotype, it is difficult to develop an effective vaccine
Moreover, even if the foot-and-mouth disease vaccine is vaccinated, there is also the disadvantage that immunity can only be maintained for a few months

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Foot and mouth disease virus vaccine composition
  • Foot and mouth disease virus vaccine composition
  • Foot and mouth disease virus vaccine composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0087] The sequence analysis of embodiment 1.FMDV serotype O

[0088] In the WRLFMD (World Reference Laboratory for Foot-and-Mouth Disease) website, in the ME report (Molecular Epidemiology Report), the VP1 region of O serotype FMDV that recently appeared in Asia was studied.

[0089] The VP1 region of FMDV has the most mutations in the P1 structural protein gene region of FMDV, which is an important site for determining immunogenicity, such as the formation of neutralizing antibodies.

[0090] The study was conducted in 21 countries including Bangladesh, Bhutan, Cambodia, China, Indonesia, India, Japan, Laos, Malaysia, Mongolia, Myanmar, Nepal, Philippines, Russia, Singapore, South Korea, Sri Lanka, Thailand and Vietnam .

[0091] (1) Cambodia

[0092] Table 1

[0093]

[0094] (2) China

[0095] Table 2

[0096]

[0097]

[0098] (3) Hong Kong, China

[0099] table 3

[0100]

[0101] (4) Indonesia: Announced no FMD in 1986

[0102] (5) Japan

[0103] ...

Embodiment 2

[0162] Embodiment 2. Preparation of novel DNA vaccine

[0163] The 81 amino acid sequences of SEQ ID NOs: 4 to 84 were aligned by Clustal / muscle. According to the alignment results, the consensus sequence of VP1 was deduced. Comparison of the derived consensus sequence with that of the conventional serotype O FMD DNA vaccine pGX9014 revealed five amino acid mismatches.

[0164] In the VP1 region of the existing serotype O FMD DNA vaccine pGX9014, five amino acids that did not match the consensus sequence were substituted. figure 1 shows the amino acid sequence (SEQ ID NO: 1) of VP1 obtained by substitution, figure 2 The nucleotide sequence of VP1 obtained by substitution is shown (SEQ ID NO: 2).

[0165] A novel FMD serotype O vaccine has been prepared using the polynucleotide shown in the nucleotide sequence of SEQ ID NO:2, the overall schematic diagram is as follows image 3 shown. Such as image 3 As shown, among the prepared recombinant nucleotides, Msc I site, VP...

Embodiment 3

[0167] Example 3. Antibody Formation Effect of Novel DNA Vaccine

[0168] 3.1 DNA vaccination

[0169] Fifteen C57BL / 6 mice (8 weeks old, female) were divided into three groups, 5 in each group, as shown below, and each group was inoculated with the vaccine of the present invention, conventional vaccine and mock plasmid 3 times every two weeks. Inoculation was performed using an electroporation device (cellectra 2000), and the DNA vaccine was administered at a concentration of 30 μg / mouse.

[0170] Group 1 (control group) - mock plasmid DNA

[0171] Group 2 (control group) - O serotype FMD DNA (pGX1414, routine vaccine)

[0172] The 3rd group (experimental group)-O serotype FMD DNA (PLS-FMD-O, vaccine of the present invention)

[0173] Blood was collected before dosing (week 0), after the second dosing (week 4) and after the third dosing (week 6) using retro-orbital blood sampling. Serum was separated from collected blood and stored at -80°C. Stored sera were lysed and ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a polypeptide involved in eliciting an immune response to foot and mouth disease virus, a polynucleotide and a composition comprising the same. The invention also relates to a method for eliciting an immune response of a subject to foot and mouth disease virus. The present invention also relates to a pharmaceutical composition for preventing foot-and-mouth disease comprising a polypeptide, polynucleotide or plasmid involved in eliciting an immune response to foot-and-mouth disease virus. Furthermore, the present invention relates to a method of preventing a foot-and-mouth disease in a subject.

Description

technical field [0001] The present invention relates to polypeptides, polynucleotides, plasmids and vaccine compositions comprising them involved in eliciting an immune response to foot-and-mouth disease virus. The invention also relates to methods of eliciting an immune response to foot-and-mouth disease virus in a subject. The present invention also relates to a pharmaceutical composition for preventing foot-and-mouth disease comprising polypeptides, polynucleotides or plasmids involved in eliciting an immune response to foot-and-mouth disease virus. Furthermore, the present invention relates to a method of preventing foot and mouth disease in a subject. Background technique [0002] Foot-and-Mouth Disease (FMD) is a viral disease affecting even-toed ungulates (Artiodactyla), including domestic animals such as cattle, pigs, sheep, goats, deer, and various wild animals, and is characterized by , nose, nipples, hooves, etc. form blisters. FMD is highly contagious, with a ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/09C12N15/42A61K39/135A61K39/295A61P31/14
CPCC07K14/005A61K39/12A61P31/14A61K2039/552A61K2039/70C12N2770/32134C12N2770/32122A61K39/00A61K39/135
Inventor 金银眞严泰起宋暻珠金旼志陆根荣
Owner 株式会社准绳生命科学
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com